Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 1.9 USD -7.32% Market Closed
Market Cap: 84.1m USD
Have any thoughts about
Adagene Inc?
Write Note

Adagene Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adagene Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Adagene Inc
NASDAQ:ADAG
Depreciation & Amortization
$980.1k
CAGR 3-Years
4%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Depreciation & Amortization
ÂĄ396.1m
CAGR 3-Years
49%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Adagene Inc
Glance View

Market Cap
84.1m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
0.96 USD
Overvaluation 49%
Intrinsic Value
Price

See Also

What is Adagene Inc's Depreciation & Amortization?
Depreciation & Amortization
980.1k USD

Based on the financial report for Dec 31, 2023, Adagene Inc's Depreciation & Amortization amounts to 980.1k USD.

What is Adagene Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
1%

Over the last year, the Depreciation & Amortization growth was -15%. The average annual Depreciation & Amortization growth rates for Adagene Inc have been 4% over the past three years , 1% over the past five years .

Back to Top